Treatment outcomes of new tuberculosis patients hospitalized in Kampala, Uganda: A prospective cohort study

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Kirenga, Bruce J ^a   Levin, Jonathan ^b,c   Ayakaka, Irene ^d   Worodria, William ^a   Reilly, Nancy ^e   Mumbowa, Francis ^e   Nabanjja, Helen ^d   Nyakoojo, Grace ^d   Fennelly, Kevin ^d,f   Nakubulwa, Susan ^b   Joloba, Moses ^a   Okwera, Alphonse ^b,g   Eisenach, Kathleen D ^h   McNerney, Ruth ⁱ   Elliott, Alison M ^a,b,i   Mugerwa, Roy D ^a,d   Smith, Peter G ⁱ   Ellner, Jerrold J ^d,j   Jones López, Edward C ^d,j  

^a MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^b UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d MAKERERE UNIVERSITY   (Uganda)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g MULAGO HOSPITAL   (Uganda)

^h UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AGE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL LOAD; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONCURRENT INFECTION; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEALTH STATUS; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; PROGNOSIS; PROSPECTIVE STUDY; RELAPSE; SEX DIFFERENCE; TUBERCULOSIS; UGANDA; HIV INFECTIONS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS; UGANDA; YOUNG ADULT;

EID: 84897554673     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090614     Document Type: Article

References (45)

1. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, et al. (2013) Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 1: CD009593.
2. Mosimaneotsile B, Talbot EA, Moeti TL, Hone NM, Moalosi G, et al. (2003) Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana. Lancet 362: 1551-1552. (Pubitemid 37410196)
3. Corbett EL, Marston B, Churchyard GJ, De Cock KM (2006) Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 367: 926-937.
4. Lawn SD, Wood R (2006) The epidemic of HIV-associated tuberculosis in sub-Saharan Africa: does this also impact non-HIV-infected individuals? Aids 20: 1787-1788. (Pubitemid 44299376)
5. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, et al. HIV coinfection in multidrug-and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 181: 80-86.
6. Whalen CC, Nsubuga P, Okwera A, Johnson JL, Hom DL, et al. (2000) Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. Aids 14: 1219-1228. (Pubitemid 30420666)
7. Palmieri F, Girardi E, Pellicelli AM, Rianda A, Bordi E, et al. (2002) Pulmonary tuberculosis in HIV-infected patients presenting with normal chest radiograph and negative sputum smear. Infection 30: 68-74. (Pubitemid 34293369)
8. Jones-Lopez EC, Ayakaka I, Levin J, Reilly N, Mumbowa F, et al. (2011) Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med 8: 15.
9. Yen YF, Yen MY, Shih HC, Deng CY (2012) Risk factors for unfavorable outcome of pulmonary tuberculosis in adults in Taipei, Taiwan. Trans R Soc Trop Med Hyg 106: 303-308.
10. Naidoo S, Douglas D (2008) Admission trends of adult TB patients at one of the largest tuberculosis hospitals in South Africa: from 2001 to 2003. Southern African Journal of Epidemiology and Infection 22: 8-12.
11. Abos-Hernandez R, Olle-Goig JE (2002) Patients hospitalised in Bolivia with pulmonary tuberculosis: risk factors for dying. Int J Tuberc Lung Dis 6: 470-474. (Pubitemid 34601861)
12. Duarte EC, Bierrenbach AL, Barbosa da Silva J, Jr., Tauil PL, de Fatima Duarte E (2009) Factors associated with deaths among pulmonary tuberculosis patients: a case-control study with secondary data. J Epidemiol Community Health 63: 233-238.
13. Volmink J, Garner P (2007) Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev: CD003343.
14. Grimwade K, Sturm AW, Nunn AJ, Mbatha D, Zungu D, et al. (2005) Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. Aids 19: 163-168. (Pubitemid 40409534)
15. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, et al. (2008) Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. Bmj 337: a257.
16. Dheda K, Lampe FC, Johnson MA, Lipman MC (2004) Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 190: 1670-1676. (Pubitemid 39411018)
17. Tabarsi P, Saber-Tehrani AS, Baghaei P, Padyab M, Mansouri D, et al. (2009) Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc 12: 14.
18. Davis JL, Worodria W, Kisembo H, Metcalfe JZ, Cattamanchi A, et al. (2010) Clinical and radiographic factors do not accurately diagnose smear-negative tuberculosis in HIV-infected inpatients in Uganda: a cross-sectional study. PLoS One 5: e9859.
19. (2000) Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 161: 1376-1395.
20. (2010) MANUAL OF THE NATIONAL TUBERCULOSIS AND. LEPROSY PROGRAMME. 2 nd. EDITION. 2010 Kampala.
21. (2010) Stop TB initiative. Treatment of tuberculosis: guidelines 2010: World Health Organization.
22. Erhabor GE, Adewole OO, Ogunlade O (2006) A five-year review of tuberculosis mortality amongst hospitalised patients in Ile-Ife. Indian J Chest Dis Allied Sci 48: 253-256.
23. Hansel NN, Merriman B, Haponik EF, Diette GB (2004) Hospitalizations for tuberculosis in the United States in 2000: predictors of in-hospital mortality. Chest 126: 1079-1086. (Pubitemid 39391235)
24. Lubart E, Lidgi M, Leibovitz A, Rabinovitz C, Segal R (2007) Mortality of patients hospitalized for active tuberculosis in Israel. The Israel Medical Association journal: IMAJ 9: 870.
25. (1996) Bactec 460 System: Product and Procedure Manual. Sparks, MD: Becton, Dickenson, and Company.
26. (1999) Bactec MGIT 960 system user's manual. Sparks, MD: Becton, Dickenson, and Company.
27. Muhumuza J, Asiimwe BB, Kayes S, Mugyenyi R, Whalen C, et al. (2006) Introduction of an in-house PCR for routine identification of M. tuberculosis in a low-income country. Int J Tuberc Lung Dis 10: 1262-1267. (Pubitemid 44713481)
28. World Health Organization. (2009) Treatment of tuberculosis: guidelines-4th ed. Geneva: World Health Organization.
29. Greenland S (2008) The need for reorientation toward cost-effective prediction: comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929). Stat Med 27: 199-206. (Pubitemid 351193639)
30. Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81: 515-526.
31. Burton NT, Forson A, Lurie MN, Kudzawu S, Kwarteng E, et al. (2011) Factors associated with mortality and default among patients with tuberculosis attending a teaching hospital clinic in Accra, Ghana. Trans R Soc Trop Med Hyg 105: 675-682.
32. van't Hoog AH, Williamson J, Sewe M, Mboya P, Odeny LO, et al. (2012) Risk factors for excess mortality and death in adults with tuberculosis in Western Kenya. Int J Tuberc Lung Dis 16: 1649-1656.
33. Henegar C, Behets F, Vanden Driessche K, Tabala M, Bahati E, et al. (2012) Mortality among tuberculosis patients in the Democratic Republic of Congo. Int J Tuberc Lung Dis 16: 1199-1204.
34. Silva DR, Menegotto DM, Schulz LF, Gazzana MB, Dalcin Pde T (2010) Factors associated with mortality in hospitalized patients with newly diagnosed tuberculosis. Lung 188: 33-41.
35. Waitt CJ, Squire SB (2011) A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis 15: 871-885.
36. Lopez-Gatell H, Cole SR, Hessol NA, French AL, Greenblatt RM, et al. (2007) Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. Am J Epidemiol 165: 1134-1142. (Pubitemid 47233709)
37. Rao VK, Iademarco EP, Fraser VJ, Kollef MH (1998) The impact of comorbidity on mortality following in-hospital diagnosis of tuberculosis. Chest 114: 1244-1252. (Pubitemid 28527393)
38. Taylor Z, Marks SM, Rios Burrows NM, Weis SE, Stricof RL, et al. (2000) Causes and costs of hospitalization of tuberculosis patients in the United States. Int J Tuberc Lung Dis 4: 931-939.
39. Shimazaki T, Marte SD, Saludar NR, Dimaano EM, Salva EP, et al. (2013) Risk factors for death among hospitalised tuberculosis patients in poor urban areas in Manila, The Philippines. Int J Tuberc Lung Dis 17: 1420-1426.
40. Greenaway C, Menzies D, Fanning A, Grewal R, Yuan L, et al. (2002) Delay in diagnosis among hospitalized patients with active tuberculosis-predictors and outcomes. Am J Respir Crit Care Med 165: 927-933. (Pubitemid 34774659)
41. Pablos-Mendez A, Sterling TR, Frieden TR (1996) The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 276: 1223-1228. (Pubitemid 26337704)
42. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2011) Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 365: 1492-1501.
43. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al. (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. New England Journal of Medicine 365: 1471-1481.
44. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, et al. (2011) Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. New England Journal of Medicine 365: 1482-1491.
45. Abdool Karim S, Naidoo K, Grobler A, Padayatchi N, Baxter C, et al. (2010) Effect of initiating antiretroviral therapy during tuberculosis treatment in HIV-infected individuals: results of a randomized controlled trial in TB-HIV co-infected patients in South Africa (SAPiT Study). N Engl J Med 362: 697-706.